News ASCO26: In vivo CAR-Ts in the spotlight Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.
Oncology CAR-NK cell therapies for solid tumours: Closing the gap bet... CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.
R&D Biotech’s biggest challenge isn’t scientific, but political ... We speak to James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy & grandson of FDR
News Iovance cuts staff on slower cell therapy sales growth Iovance will slash 19% of its headcount in a restructuring that follows slower-than-expected sales growth for melanoma cell therapy Amtagvi.
News ADA: Vertex closer to weaning type 1 diabetics off insulin A cell therapy developed by Vertex Pharma has allowed 10 of 12 patients with type 1 diabetes to control their blood sugar without insulin.
R&D Cell therapy transportation and storage with hydrogels Hydrogels are revolutionising cell therapy storage – discover how they tackle cold chain challenges and reduce costs while preserving cell viability.
Oncology ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C... At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.